2023-507027-37-00已完成1 期
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 10
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS – Scientific Request, Dr. Falk Pharma GmbH
Scientific
Dr. Falk Pharma GmbH
研究点 (10)
Loading locations...
相似试验
已完成
1 期
A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.2023-505299-31-00Abivax32
招募中
1 期
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.2024-514561-20-00Abivax48
已完成
1 期
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic functionUrticariaAllergic rhinitis2022-500774-34-00Noucor Health S.A.44
招募中
4 期
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected MelanomaMelanoma2025-522307-14-00Intas Pharmaceuticals Limited19
招募中
1 期
Phase 1 study to investigate the pharmacokinetic profile and safety of 3 testosterone gel formulations in postmenopausal female participants.2025-522726-12-00Chemo Research S.L.24